N
Northstar Nuclear Medicine
Providing patients global access to game-changing radiopharmaceuticals
About Northstar Nuclear Medicine
NorthStar Medical Radioisotopes is a pioneering company in the field of diagnostic and therapeutic radiopharmaceuticals. They develop innovative products and technologies that are shaping the future of this industry. Their primary market is the healthcare sector, where they supply stable, reliable, and environmentally-friendly radioisotopes for patient care and clinical research.
Read full description
The company's business model revolves around the production and distribution of these radioisotopes. They source these materials domestically, ensuring a consistent supply chain that meets the critical needs of their clients, which include hospitals, research institutions, and pharmaceutical companies.
NorthStar Medical Radioisotopes has a strong track record and is recognized as an emerging global leader in the field of radiopharmaceuticals. They have a vision for the future and are committed to advancing radioisotope technology to shape a better world.
The company has also been involved in several strategic partnerships and agreements. For instance, they have a long-term supply agreement with Curadh MTR for the therapeutic radioisotope Actinium-225 (Ac-225). They have also executed a supply agreement with Bayer for the same radioisotope.
In addition, the company is actively involved in clinical trials. They recently announced that the first participant has been treated using their Electron Accelerator-produced Copper-67 (Cu-67) in a Phase I/IIa Theranostic Clinical Trial for the treatment of Neuroblastoma.
At a glance
- Status
- Operational
- Founded
- 2006
- Headquarters
- Madison, United States
- Employees
- 315
- Open positions
- 17
- Dealroom signal
- 71.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, Medical Devices
- Sector
- Biotech & Life Sciences, Risk Management, Biotechnology, Oncology, Cardiology and cardiovascular, Health Diagnostics, Biotech and Pharma, Radioisotope Therapeutics, Hard Tech, Radiopharmaceuticals, DT and LS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Aug 2021 | $37M | — | National Nuclear Security Administration | — |
| EARLY VCOther financing | Apr 2019 | $75M | $300M | Oberland Capital | — |
Growth signals
Latest recorded traffic for Northstar Nuclear Medicine is 2.9K monthly website visits, down 31% over the last three months. Northstar Nuclear Medicine's team grew 3.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Nuclear Security Administration
Series A3 investors entered at this stage
Illinois Ventures- SAStateline Angels
Oberland Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Northstar Nuclear Medicine on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Northstar Nuclear Medicine’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.